Aligos Therapeutics Inc.

Last updated September 27, 2026

Favorite this organization

Organization details

Legal name: Aligos Therapeutics Inc.
Ownership: Public
Status: Active
Sector (GICS): Health Care
SIC code: 2836 — Biological Products, (No Diagnostic Substances)
Jurisdiction of incorporation: Delaware
Headquarters city: South SAN Francisco
Headquarters state / province: California
Headquarters country: United States
Fiscal year end: December
Ticker symbol: ALGS
Primary stock exchange: Nasdaq

Identifiers

SEC CIK: 0001799448

Board of directors

Follow this board

Bridget A. Martell · Director
Since 2023
Carole Nuechterlein · Director
Since 2023
Heather Preston · Director
Since 2024
Jack Nielsen · Director
Since 2023
James Paul Scopa · Director
Since 2023
Lawrence Blatt · Director · President and CEO
Since 2023
Leonid Beigelman · Director · President
Since 2023
Margarita Chavez · Director
Since 2024
Peter Hirth · Director
Since 2023

Chief executives

Lawrence Blatt · Chief Executive Officer

Dates unknown

Director election results

Annual meeting of June 25, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Carole Nuechterlein

95.7%

Board connections

4 of this board's directors also sit on 7 other boards. 7 are in the same sector.

Shared director Other board Same sector

ALX Oncology Holdings Inc. Same sector
via Jack Nielsen
Achieve Life Sciences Inc. Same sector
via Bridget A. Martell
Delcath Systems Inc. Same sector
via Bridget A. Martell
Freenome Inc. Same sector
via Carole Nuechterlein
Harmony Biosciences Holdings Inc. Same sector
via Jack Nielsen
Instil Bio Inc. Same sector
via Jack Nielsen
Vaxcyte Inc. Same sector
via Peter Hirth

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months: $0; 0 purchases by 0 insiders
Sold, last 12 months: $0; 0 sales by 0 insiders

Date	Insider	Transaction	Shares	Price	Value
Oct 25, 2023	Carole Nuechterlein Director, 10% owner	Open-market purchase	+7,933,601	$0.76	$6,029,537
Oct 25, 2023	Lawrence Blatt Director, Officer (Chief Executive Officer)	Grant or award	+610,277	$0.76	$463,811
Oct 25, 2023	James Paul Scopa Director	Grant or award	+183,083	$0.76	$139,143

Peers

Compare boards

Organizations in the same sector, closest in location and size first.

3M Company NYSE: MMM · ST Paul, United States Organization ABVC BioPharma Inc. Nasdaq: ABVC · Fremont, United States Organization ACADIA Pharmaceuticals Inc. Nasdaq: ACAD · SAN Diego, United States Organization ADMA Biologics Inc Nasdaq: ADMA · Ramsey, United States Organization

Questions about Aligos Therapeutics Inc.

Who is the CEO of Aligos Therapeutics Inc.?

Lawrence Blatt is Aligos Therapeutics Inc.'s Chief Executive Officer.

How many directors are on Aligos Therapeutics Inc.'s board?

Aligos Therapeutics Inc.'s board has 9 directors: Bridget A. Martell, Carole Nuechterlein, Heather Preston, Jack Nielsen, James Paul Scopa, Lawrence Blatt, Leonid Beigelman, Margarita Chavez and Peter Hirth.

How is Aligos Therapeutics Inc. connected to…? → Spot something wrong? Report a correction

Embed this board on your site

Paste this where the board should appear. It always shows the current directors and links back here.

<div data-bod-board="aligos-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>

Reviews (0)

No reviews yet. Be the first to write one.